C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

Adult CIRB - Early Phase Emphasis Meeting Agenda

October 20, 2026

I Amendment

10674, A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination with ASTX727 and Venetoclax in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (Version Date 08/12/26)

II Continuing Review

10492, Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer (Version Date 07/31/26)

III Continuing Review

10563, A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas (Version Date 04/17/26)

IV Continuing Review

10655, Phase I Clinical Trial of CA-4948 (emavusertib) in Combination with FOLFOX Plus Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer (Version Date 07/15/26)
